Serum IGF-1 and IGF-1Ec in Malignancy Assessment

NCT ID: NCT07151807

Last Updated: 2025-09-03

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 100 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-04-01
• Study Completion Date: 2026-12-31

Brief Summary

This cross-sectional study investigates the relationship between serum IGF-1 and IGF-1Ec (E-peptide/MGF) levels and tumor burden in patients with solid tumors. By analyzing serum samples using ELISA and correlating them with clinical data such as tumor stage, size, metastasis, and lymph node involvement, the study aims to explore whether these biomarkers-particularly IGF-1Ec and the IGF-1Ec/IGF-1 ratio-can reflect tumor progression and serve as potential prognostic indicators.

Detailed Description

Background: Insulin-like Growth Factor-1 (IGF-1) and its splice variant IGF-1Ec (also known as Mechano Growth Factor, MGF) play critical roles in cell proliferation, survival, and tumor progression. Recent evidence suggests that IGF-1Ec may act independently of the classical IGF-1 receptor pathway and contribute to aggressive tumor behavior. However, data on serum IGF-1Ec levels and their correlation with clinical tumor burden remain limited.

Objective: This cross-sectional analytical study aims to quantify serum IGF-1 and IGF-1Ec levels in patients with solid tumors and investigate their association with tumor burden parameters such as clinical stage, tumor size, lymph node involvement, and metastasis. The IGF-1Ec/IGF-1 ratio will also be evaluated as a potential prognostic biomarker.

Methods: Serum samples will be collected from approximately 60 patients diagnosed with solid tumors. IGF-1 and IGF-1Ec levels will be measured using validated ELISA kits. Clinical tumor burden will be assessed from medical records (TNM staging, metastasis, tumor diameter). Statistical analysis will include group comparisons and correlation tests.

Conditions

Cancer; Solid Tumor Malignancies; IGF1R; Solid Cancers

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Study Groups

1

The study group will consist of at least 60 adult patients (aged 18 and older) with histologically confirmed solid tumors who are clinically stable and have not yet started or are in the early phase of standard chemotherapy. Participants will be recruited from the outpatient and inpatient oncology units at Çanakkale Onsekiz Mart University. Individuals with hematological malignancies, organ failure, or conditions/medications affecting IGF-1 levels will be excluded.

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 years
• Histologically confirmed diagnosis of a solid tumor
• Clinically stable condition, prior to chemotherapy or during standard follow-up
• Ability to provide informed consent

Exclusion Criteria

• Hematological malignancies (e.g., leukemia, lymphoma)
• Acute or chronic liver or kidney failure
• Current use (within 1 month) of corticosteroids, growth hormone, or medications affecting IGF-1 levels
• Pregnancy or lactation
• Coagulopathy or severe anemia preventing safe venipuncture

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Çanakkale Onsekiz Mart University

OTHER

Sponsor Role: lead

Responsible Party

Cemre Aydeğer

Research asistant, PhD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Çanakkale Onsekiz Mart University

Çanakkale, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

COMU-FNO-4

Identifier Type: -

Identifier Source: org_study_id